Daily Brief Health Care: Rainbow Children’s Medicare, Boston Scientific, Astrazeneca Plc Spons Adr, Cooper Cos, Davita Healthcare Partners, Henry Schein, Hologic Inc, Regeneron Pharmaceuticals, Roivant Sciences Ltd, Royalty Pharma and more

Key points (machine generated)

• Rainbow Children’s Medicare operates a hub hospital with multiple spoke hospitals in various locations, allowing them to serve a wide geographical area and reach a larger patient base.
• The company has a strong financial performance, with profitable growth and operating cash.
• Rainbow Children’s Medicare aims to address the underserved niche pediatric market in India and capitalize on the country’s large adolescent population, presenting significant growth potential. They plan to expand their operational bed capacity by 40% by 2026.

This article is sourced from an online content aggregator through publicly available sources and is displayed below for general informational purposes only. This article was originally published 3 months ago on Value Investors Club.

• Boston Scientific Corporation delivered an all-around beat in the previous quarter, demonstrating sustained momentum driven by new product innovations, clinical evidence, and the dedication of global teams.
• In Q3, the company achieved remarkable operational and organic growth, with total sales increasing by 11% operationally and 10% organically compared to Q3 ’22.
• The adjusted EPS for Q3 reached $0.50, a 15% increase over Q3 ’22, exceeding the guidance range of $0.46 to $0.48.

• AstraZeneca PLC delivered a mixed result in the recent quarter, with revenues below market expectations, but managed to surpass the analyst consensus regarding earnings.
• They reported a 5% increase in total revenue, reaching $33.8 billion in the first nine months of the year.
• Notably, the non-COVID-19 medicines demonstrated a robust 15% growth, offsetting the $2.9 billion decline in revenue from COVID-19 medicines.

• The Cooper Companies delivered a mixed result in Q4, with revenues above market expectations, but it failed to surpass the analyst consensus in terms of earnings.
• CooperVision’s outstanding performance stands out, achieving an impressive 11th consecutive quarter of double-digit organic growth.
• MiSight’s impressive 41% revenue growth in myopia management, driven by positive trends in the Americas and EMEA, solidifies Cooper’s position in proactive myopia control.

• DaVita Inc. delivered a solid result and managed an all-around beat last quarter.
• Financially, the third quarter saw impressive results, with adjusted operating income reaching $525 million and adjusted earnings per share at $2.85, surpassing expectations.
• Looking ahead, DaVita revises its 2023 adjusted operating income guidance to $1.65 billion to $1.725 billion and adjusted earnings per share to a new range of $7.80 to $8.30.

• In the third quarter, Henry Schein reported mediocre financial performance with below-par revenues and earnings that were just about in line with analyst expectations.
• Despite decreased PPE and COVID-19 test sales, the company achieved commendable total sales and non-GAAP diluted EPS growth.
• As Henry Schein progresses through its BOLD+1 Strategic Plan, the management remains confident in the stability of dental and medical markets, adhering to strategic priorities despite cybersecurity incidents.

• Hologic, Inc. managed to exceed analyst expectations in terms of revenue as well as earnings, concluding Q4 with total revenue at $945.3 million and non-GAAP earnings per share at $0.89.
• The Q4 results highlighted a 16.7% total organic revenue growth, excluding COVID-19, with double-digit growth in all divisions.
• Notably, the company deployed substantial capital for share repurchases in Q4 2023 and Q1 2024, with an additional $500 million accelerated share repurchase program announced.

• Regeneron Pharmaceuticals, Inc. delivered an all-around beat in the previous quarter, witnessing a commendable 15% surge in total revenues.
• The notable upswing was propelled by increased Sanofi collaboration revenues and a remarkable 62% growth in LIBTAYO global net product sales, complemented by a 50% surge in Dupixent global net product sales, totaling $3.1 billion.
• In the quarter, the management highlighted the successful launch of EYLEA HD, which achieved $43 million in net product sales within the final six weeks of the quarter.

Key points (machine generated)

• Roivant Sciences is set to close a $7.25 billion deal with Roche for Telavant, bringing their total value to $12 billion.
• Despite the negative sentiment in the biotech industry, ROIV shares have the potential for over 100% upside with minimal downside, making it an attractive investment opportunity.
• ROIV is likely to return capital to shareholders, benefiting existing holders such as Softbank and Sumitomo.

This article is sourced from an online content aggregator through publicly available sources and is displayed below for general informational purposes only. This article was originally published 3 months ago on Value Investors Club.

• Royalty Pharma plc delivered mixed results for the previous quarter, with revenues below the analyst consensus.
• The fiscal triumphs included a notable 9% augmentation in adjusted cash receipts, a parallel ascent in adjusted EBITDA, and a remarkable 10% surge in adjusted cash flow.
• The expanded partnership with PTC was particularly laudable, resulting in procuring additional royalties for Evrysdi, a treatment for spinal muscular atrophy.